Gastrointestinal (GI) cancers comprise a significant number of cancer cases worldwide and contribute to a high percentage of cancer-related deaths. To improve survival rates of GI …
X Wang, H Zhu, Y Jiang, Y Li, C Tang… - Briefings in …, 2022 - academic.oup.com
Although drug combinations in cancer treatment appear to be a promising therapeutic strategy with respect to monotherapy, it is arduous to discover new synergistic drug …
The past decade has seen an explosion in the collection of genotype data in domains as diverse as medicine, ecology, livestock and plant breeding. Along with this comes the …
Simple Summary The heterogeneity of complicated diseases like cancer negatively affects patients' responses to treatment. Finding homogeneous subgroups of patients within the …
M Ray, S Zhao, S Wang, A Bohl… - BMC Health Services …, 2023 - Springer
Background Risk-adjustment (RA) models are used to account for severity of illness in comparing patient outcomes across hospitals. Researchers specify covariates as main …
B Patel, B Gelat, M Soni, P Rathaur… - Current …, 2024 - ingentaconnect.com
Different diseases can be treated with various therapeutic agents. Drug discovery aims to find potential molecules for existing and emerging diseases. However, factors, such as …
Y Li, H Zhu, X Wang, Q Liu - International Symposium on Bioinformatics …, 2023 - Springer
Synergistic drug combination is a promising solution to cancer treatment. Since the combinatorial space of drug combinations is too vast to be traversed through experiments …
With more and more data being generated in the life sciences the application of computational algorithms and Artificial Intelligence (AI) for drug discovery in general, and …
NA Patel - Journal of Law and the Biosciences, 2017 - academic.oup.com
In 2013, Valeant Pharmaceuticals, a specialty pharmaceutical company, received the intellectual property rights to a lead poisoning treatment known as Calcium EDTA as part of …